SecBot SecBot
144 ·Filed Oct 27, 2026

CLGN

CollPlant Biotechnologies Ltd
NEUTRAL
Impact 2/10
Processed8h 15m ago SEC0001949846-26-000621
Form 144 — notice of proposed sale of securities

Price Chart

Loading chart...

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001949846-26-000621
Document: 0001949846-26-000621-index.html0001949846-26-000621
Document: 0001949846-26-000621.txt0001949846-26-000621
21 reports for CLGN
Performance horizon
100% Hit rate @ T+1 9 of 9 directional calls Went positive at some point 9 of 9 best @ T+60▲ +25.17%May 29, 2026
Filters
Rows
Reports for CLGN — sortable, filterable
TypeNow
Oct 27, 2026
today
144
NEUTRAL ★ 2/10
$3.78awaiting T+1—$3.90 (+3.17%)
Oct 19, 2026
8d ago
3
NEUTRAL ★ 2/10
$3.88 $3.76▼ −3.22%▼ −3.75%$3.90 (+0.52%)
Oct 15, 2026
12d ago
6-K
BEARISH ★ 6/10
$3.68 $3.63▲ +1.49%▲ +0.39%$3.90 (−5.98%)
Oct 9, 2026
18d ago
6-K
BEARISH ★ 5/10
$4.02 $3.91▲ +2.74%▲ +2.72%$3.90 (+2.99%)
Oct 8, 2026
19d ago
SC 13G
NEUTRAL ★ 3/10
$3.97 $3.51▼ −11.59%▼ −12.19%$3.90 (−1.76%)
Oct 8, 2026
19d ago
SC 13D/A
NEUTRAL ★ 3/10
$3.97 $3.51▼ −11.59%▼ −12.19%$3.90 (−1.76%)
Oct 6, 2026
21d ago
6-K
NEUTRAL ★ 3/10
$3.39 $3.46▲ +2.06%▲ +2.30%$3.90 (+15.04%)
Sep 30, 2026
27d ago
6-K
BEARISH ★ 7/10
$3.57 $3.46▲ +3.08%▲ +3.82%$3.90 (−9.24%)
Sep 30, 2026
27d ago
Press Release
BEARISH ★ 5/10
$3.57 $3.46▲ +3.08%▲ +3.82%$3.90 (−9.24%)
Sep 24, 2026
4w ago
6-K
NEUTRAL ★ 4/10
$4.12 $4.25▲ +3.16%▲ +2.61%$3.90 (−5.34%)
Showing 10 of 21

US Market Status

Market Closed — Opens Wed (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Oct 27, 2026

Fresh CLGN Intelligence

Analysis is for subscribers only.

Subscribe for Full Access